Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Deletion of Gba in neurons, but not microglia, causes neurodegeneration in a Gaucher mouse model
Hannah B.D. Duffy, Colleen Byrnes, Hongling Zhu, Galina Tuymetova, Y. Terry Lee, Frances M. Platt, Richard L. Proia
Hannah B.D. Duffy, Colleen Byrnes, Hongling Zhu, Galina Tuymetova, Y. Terry Lee, Frances M. Platt, Richard L. Proia
View: Text | PDF
Research Article Genetics Neuroscience

Deletion of Gba in neurons, but not microglia, causes neurodegeneration in a Gaucher mouse model

  • Text
  • PDF
Abstract

Gaucher disease, the most prevalent lysosomal storage disease, is caused by homozygous mutations at the GBA gene, which is responsible for encoding the enzyme glucocerebrosidase. Neuronopathic Gaucher disease is associated with microgliosis, astrogliosis, and neurodegeneration. However, the role that microglia, astrocytes, and neurons play in the disease remains to be determined. In the current study, we developed inducible, cell-type-specific Gba-KO mice to better understand the individual impacts of Gba deficiencies on microglia and neurons. Gba was conditionally knocked out either exclusively in microglia or neurons or throughout the body. These mouse models were developed using a tamoxifen-inducible Cre system, with tamoxifen administration commencing at weaning. Microglia-specific Gba-KO mice showed no signs of disease. However, the neuron-specific Gba KO resulted in a shortened lifespan, severe weight loss, and ataxia. These mice also had significant neurodegeneration, microgliosis, and astrogliosis accompanied by the accumulation of glucosylceramide and glucosylsphingosine, recapitulating Gaucher disease–like symptoms. These surprising findings reveal that, unlike the neuron-specific Gba deficiency, microglia-specific Gba deficiency alone does not induce disease. The neuronal Gaucher disease mouse model, with a median survival of 16 weeks, may be useful for future studies of pathogenesis and the evaluation of therapies.

Authors

Hannah B.D. Duffy, Colleen Byrnes, Hongling Zhu, Galina Tuymetova, Y. Terry Lee, Frances M. Platt, Richard L. Proia

×

Figure 4

Gba-nKO, but not Gba-mKO, mice exhibit neurological decline and a shortened lifespan.

Options: View larger image (or click on image) Download as PowerPoint

Gba-nKO, but not Gba-mKO, mice exhibit neurological decline and a short...
(A) Bodyweight of female and male Gba-mKO, Gba-nKO, and Gba-wbKO mice. Mice were weighed weekly beginning at weaning (when tamoxifen administration began). Gba-mKO mouse (n = 19–31/group) weights are displayed up to 12 months of age. Gba-nKO (n = 35–38/group) and Gba-wbKO (n = 31–57/group) mouse weights are shown up to the end of the lifespan. Gba-mKO mice gained weight at a similar rate to that of controls. Gba-nKO mice began to decline in weight at about 12 weeks of age. Gba-wbKO mice declined in weight rapidly although the initial time point was variable. Mixed-effects model and Holm-Šidák’s multiple comparisons test. (B) Ataxia scores based on a battery of tests in Gba-nKO mice. Two-way ANOVA and Holm-Šidák’s multiple comparisons test. n = 11–13. (C) Survival curves of Gba-mKO, Gba-nKO, and Gba-wbKO mice compared with control mice. If survival differences were not significant, results from the different sexes were collapsed. Log-rank (Mantel-Cox) test. n = 37–66. (D) Brain weight of Gba-mKO (n = 10), -nKO (n = 20–21), and -wbKO (n = 5–16) mice compared with that of age-matched controls. Unpaired t test. (E) Spleen and liver weights of Gba-wbKO mice graphed as a percentage of body weight. Unpaired t test. n = 5–11. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts